Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
16 hedge funds and large institutions have $1.51M invested in Titan Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 6 closing their positions.
53% more capital invested
Capital invested by funds: $988K → $1.51M (+$523K)
0.13% more ownership
Funds ownership: 0.17% → 0.29% (+0.13%)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
20% less funds holding
Funds holding: 20 → 16 (-4)
37% less call options, than puts
Call options by funds: $257K | Put options by funds: $411K
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$397K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$329K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$124K |
| 4 |
VF
Virtu Financial
New York
|
+$83.3K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$119K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$109K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$69K |
| 4 |
Millennium Management
New York
|
-$50K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$38K |
TTNP Hedge Fund Activity: Q2 2021 in Review
16 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q2 2021, worth a combined $1.51M — up 53% from $988K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TTNP and 2 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Morgan Stanley, adding an estimated $397K. The largest seller was GSA Capital Partners, exiting entirely with an estimated $119K sold.
- 16 institutional investors held Titan Pharmaceuticals (TTNP) as of Q2 2021, down from 20 in Q1 2021.
- Funds reported $1.51M of Titan Pharmaceuticals stock for Q2 2021, up 53% quarter-over-quarter.
- 2 funds opened new Titan Pharmaceuticals positions in Q2 2021 and 6 closed out, a net change of -4 holders.
- The largest Titan Pharmaceuticals buyer in Q2 2021 was Morgan Stanley, an estimated $397K added.
- The largest Titan Pharmaceuticals seller in Q2 2021 was GSA Capital Partners, an estimated $119K sold.
Based on aggregated 13F filings for Q2 2021.